Achondroplasia Natural History Multicenter Clinical Study
Part of paid clinical trials in Baltimore, Maryland.
- Sponsor
- Johns Hopkins University
- Study ID
- NCT02597881
- Status
- Recruiting
Conditions
- Achondroplasia
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
The purpose of this study is to create an electronic registry to house phenotypic information from patients with achondroplasia. The initial focus of this registry will be to include U.S. patients with achondroplasia. Once populated, the collective data can be queried to pursue clinical research questions pertaining to health outcomes and treatment options for patients with this conditions. The registry is longitudinal in nature with the functionality to retrospectively enter patients' clinical data from the prenatal period up through the most recent encounter, with all intervening data entered in a chronologic fashion.
Key Dates
- Start date
- Apr 30, 2016
- Status verified
- Mar 2026
- Primary completion
- Dec 31, 2030
- Completion
- Dec 31, 2030
Study Design
- Enrollment
- 1,500 participants (estimated)
Primary Outcome Measure
Collection of growth measurements of patients with Achondroplasia using chart reviews [ Time Frame: 3 years ]
Central Contacts
- Julie Hoover-Fong, MD, PhD4106140977
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Johns Hopkins University | Baltimore | Maryland | 21205 |
Find similar trials in Baltimore, MD
Related Studies
- Extension Study of Infigratinib in Children With Achondroplasia (ACH)PHASE2 · Enrolling By Invitation · QED Therapeutics, a BridgeBio company · Oakland, California
- A Study of TYRA-300 in Children With Achondroplasia: BEACH301PHASE2 · Recruiting · Tyra Biosciences, Inc · Torrance, California
- Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)PHASE2 · Recruiting · QED Therapeutics, a BridgeBio company · Oakland, California
- Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaPHASE2/PHASE3 · Recruiting · BioMarin Pharmaceutical · Oakland, California